20.16
-0.23
(-1.13%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 20.00 - 20.31 |
| 52 week | 16.18 - 23.96 |
| Open | 20.30 |
| Vol / Avg. | 2.21M/3.11M |
| Mkt cap | 5.43B |
| P/E | - |
| Div/yield | - |
| EPS | -0.38 |
| Shares | 269.31M |
| Beta | 1.17 |
| Inst. own | 100% |
Events
Jul 29, 2013
Q3 2013 Hologic Earnings Release
Jun 12, 2013
Hologic at Goldman Sachs Healthcare Conference
- 2:20PM EDT -
Jun 12, 2013
Hologic at William Blair Growth Stock Conference
- 1:40PM EDT -
May 14, 2013
Hologic at Bank of America Merrill Lynch Health Care Conference
May 6, 2013
Q2 2013 Hologic Earnings Conference Call -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -8.34% | -3.68% |
| Operating margin | 0.37% | 3.56% |
| EBITD margin | - | 26.01% |
| Return on average assets | -1.97% | -0.89% |
| Return on average equity | -6.86% | -2.50% |
| Employees | 6,157 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women. The Company operates in four segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Company sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. On August 1, 2012, the Company acquired Gen-Probe Incorporated (Gen-Probe). Gen-Probe is engaged in molecular diagnostics products and services, which are used to diagnose human diseases, screen donated human blood and test transplant compatibility. In March 2013, it announced that it has completed its sale of the LIFECODES business unit to Immucor, Inc.
Officers and directors
| David R. LaVance Jr. | Independent Chairman of the Board | |
| Robert A. Cascella | President, Chief Executive Officer, Director | |
| Glenn P. Muir | Chief Financial Officer, Executive Vice President - Finance & Administration, Director | |
| Jay A. Stein | Chairman Emeritus, Senior Vice President & Chief Technical Officer | |
| Mark J. Casey | Senior Vice President, Chief Administrative Officer, General Counsel, Secretary | |
| David P Harding | Senior Vice President, General Manager - International | |
| Rohan Hastie | Senior Vice President, Group General Manager - Diagnostics | |
| Peter K. Soltani | Senior Vice President, General Manager - Breast Health Line of Business | |
| David J. Brady | Senior Vice President - Human Resources | |
| Scott T. Garrett | Director |